Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia

被引：15

作者：

Alberts, SR ^{[1
]}

Blute, ML

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Urol, Rochester, MN 55905 USA

来源：

UROLOGY | 2001年 / 57卷 / 4A期

关键词：

D O I：

10.1016/S0090-4295(00)00971-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

High-grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor for prostatic adenocarcinoma, The prevalence of prostatic intraepithelial neoplasia (PIN) increases with advancing age. Autopsy studies suggest that PIN may precede the development of prostatic adenocarcinoma by up to 10 years. As such, HGPIN is believed to be a marker of increased risk. This provides a potential opportunity for chemoprevention. Flutamide is I agent with potential activity and limited side effects that may act to prevent or delay the onset of prostatic adenocarcinoma in men with HGPIN. A clinical trial is currently underway to assess the efficacy of flutamide.

引用

页码：188 / 190

页数：3

共 29 条

[1]

Bostwick DG, 1996, CANCER, V78, P330, DOI 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO

[2]

2-W

[3]

BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO

[4]

2-I